Holen Sie sich die Stockscreener-App
239.46
0.33%
-0.61
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Nigeria
Learn Why The Bull Case For Jazz Pharmaceuticals Stock Could Change Following FDA Drug Approval - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Strong Buy Ratings and a 17.28% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals Stock Price Forecast. Should You Buy JAZZ? - StockInvest.us
Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone? - Yahoo Finance
Four September conference talks will include Jazz Pharmaceuticals - Stock Titan
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report? - Eastern Progress
Finance Watch: Multibillion-Dollar Debt Offerings Fuel Growth - insights.citeline.com
Jazz Pharmaceuticals PLC (JAZZ) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Why Jazz Pharmaceuticals (JAZZ) Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next - simplywall.st
Insider plans more Jazz (NASDAQ: JAZZ) share sales—but how big is this next trade? - Stock Titan
JAZZ Rises on Updated OS Results From Gastric Cancer Study - Yahoo Finance
Canaccord reiterates Jazz Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Nigeria
Jazz reports Phase III trial interim results for Ziihera combination - clinicaltrialsarena.com
Jazz Pharmaceuticals Raises $1.25 Billion Via 1.875% Exchangeable Notes Due 2032 - TradingView
Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 1,527 shares in 2026 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 3,507 shares - Stock Titan
No-Moat Jazz's Growth Supported by Strong Clinical Data for Ziihera and Expanding Opportunity - Morningstar
Jazz Pharma (NASDAQ: JAZZ) director to sell 3,507 shares in 2026 - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director plans $858K stock sale - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director may sell 3,507 shares - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) director may sell 3,507 shares - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director to sell 3,507 shares - Stock Titan
Jazz Pharma (NASDAQ: JAZZ) director plans sale after 18,000 shares sold - Stock Titan
Positive Phase 3 Survival Results in HER2+ Advanced GEA – Jazz Pharmaceuticals - Oncodaily
Cancer drug decision could swing Jazz Pharmaceuticals' beatBizwomen - The Business Journals
JAZZ Looks 61.2% Overvalued on GF Value™ as Positive Trial Data Boosts Sentiment - GuruFocus
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA - PR Newswire
Jazz Pharmaceuticals (JAZZ) Stock Analysis: A 17% Upside Potential Lights Up Investor Interest - DirectorsTalk Interviews
Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera - simplywall.st
Jazz Pharmaceuticals (JAZZ) Stock May Be Undervalued As FDA Cancer Approval Lands - simplywall.st
Jazz Pharmaceuticals prices $1.1B exchangeable notes offering By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases - TradingView
JAZZ PHARMACEUTICALS PLC : DEUTSCHE BANK RAISES TARGET PRICE TO $300 FROM $287 - webull.com
Jazz Pharmaceuticals plans $1 billion exchangeable notes offering By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Plans $1 Billion Exchangeable Senior Notes Due 2032 - marketscreener.com
Jazz Pharmaceuticals plans $1 billion exchangeable notes offering - Investing.com
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA - Yahoo Finance
Jazz Pharmaceuticals stock rises after FDA approves Ziihera By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals stock hits all-time high at 265.54 USD By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals stock hits all-time high at 265.54 USD - Investing.com
Jazz Pharmaceuticals receives FDA approval for Ziihera HER2-positive GEA treatment - grafa.com
Jazz Pharma's fresh tune: New CEO wants to make longtime Bay Area drugmaker 'a true innovator' - The Business Journals
Advisors Preferred LLC Acquires New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative - simplywall.st
Great Lakes Advisors LLC Invests $8.15 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Announces $820 Million Acquisition of Actio Biosciences - Global Legal Chronicle
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jessica Merrill: Mid-Cap Biopharma's $1B-Plus Deal Surge Could Spawn the Next Amgen - finance.biggo.com
Jazz Pharmaceuticals (JAZZ) Stock Analysis: A Glimpse Into The 14.86% Potential Upside - DirectorsTalk Interviews
Jazz Pharmaceuticals PLC at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Understanding HER2 Expression in Gastroesophageal AdenocarcinomaJazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Jazz Pharmaceuticals plc: Target Price Consensus and Analysts Recommendations | JAZZ | IE00B4Q5ZN47 - marketscreener.com
Irish Jazz Pharmaceuticals acquires American Actio for $1.32 billion - AKM.RU
Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed - simplywall.st
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout (JAZZ) - Seeking Alpha
Wedge Capital Management L L P NC Sells 33,467 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
JAZZ Maintained by Morgan Stanley -- Price Target Raised to $283 - GuruFocus
Jazz Pharmaceuticals (JAZZ) Acquires Actio Biosciences for $820 Million - GuruFocus
Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says - marketscreener.com
Morgan Stanley Adjusts Jazz Pharmaceuticals PT to $283 From $280, Maintains Overweight Rating - marketscreener.com
Jazz Pharmaceuticals buys Actio for up to $1.3bn - BioXconomy
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront - Yahoo Finance
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):